...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical journal of the American Society of Nephrology: CJASN >Clinical utility of biomarkers of AKI in cardiac surgery and critical illness
【24h】

Clinical utility of biomarkers of AKI in cardiac surgery and critical illness

机译：AKI生物标志物在心脏手术和重症疾病中的临床应用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AKI is a common and serious complication that is associated with several adverse outcomes in hospitalized patients. The past several years have seen a large number of multicenter investigations of biomarkers of AKI in the setting of cardiac surgery and critical illness. This review summarizes these biomarker results to identify applications for clinical use. The Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) study showed that blood and urine biomarkers measured preoperatively, immediately postoperatively, and at the time of the clinical increase in serum creatinine in the setting of cardiac surgery all had the ability to improve patient risk stratification for a variety of important clinical end points. Analyses of biomarkers concentrations from the Acute Respiratory Distress Syndrome Network, EARLY ARF, and other studies of critically ill subjects have similarly shown that biomarkers measured early in the clinical course can forecast the development of AKI and need for renal replacement therapy as well as inpatient mortality. Although biomarkers have informed the diagnosis, prognosis, and treatment of AKI and are inching closer to clinical application, large multicenter interventional clinical trials to prevent AKI using biomarkers should continue to be an active area of clinical investigation.
机译：AKI是常见且严重的并发症，与住院患者的一些不良结局有关。在过去的几年中，在心脏手术和严重疾病的环境中，已经进行了许多有关AKI生物标志物的多中心研究。这篇综述总结了这些生物标志物的结果，以鉴定临床应用。 AKI的转化研究调查生物标志物终点（TRIBE-AKI）研究显示，术前，术后立即以及在心脏外科手术中血清肌酐临床升高时测量的血液和尿液生物标志物均具有改善患者病情的能力。各种重要临床终点的风险分层。急性呼吸窘迫综合征网络，EARLY ARF和其他危重患者研究的生物标志物浓度分析表明，在临床过程的早期测量的生物标志物可以预测AKI的发展，肾脏替代疗法的需要以及住院患者的死亡率。尽管生物标志物已为AKI的诊断，预后和治疗提供了信息，并且已接近临床应用，但使用生物标志物预防AKI的大型多中心介入临床试验应继续成为临床研究的活跃领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号